| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 46.10 | 2419 |
| Intrinsic value (DCF) | 0.85 | -54 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 45.20 | 2370 |
Innate Pharma S.A. (NASDAQ: IPHA) is a clinical-stage biotechnology company headquartered in Marseille, France, specializing in the discovery and development of innovative immunotherapies for cancer treatment. The company focuses on harnessing the innate immune system through therapeutic antibodies targeting oncology indications. Its pipeline includes Lacutamab (IPH4102), a promising anti-KIR3DL2 antibody in Phase II trials for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), as well as Monalizumab, an immune checkpoint inhibitor in Phase III trials for solid tumors. Innate Pharma also explores novel mechanisms like CD39 and CD73 inhibition (IPH5201, IPH5301) and NK cell engagers (IPH6101) to enhance antitumor immunity. The company has strategic collaborations with AstraZeneca, Sanofi, and Novo Nordisk, leveraging partnerships to accelerate clinical development and commercialization. Operating in the high-growth oncology immunotherapy sector, Innate Pharma aims to address unmet medical needs in hematologic malignancies and solid tumors while maintaining a diversified pipeline.
Innate Pharma presents a high-risk, high-reward investment opportunity in the competitive oncology immunotherapy space. The company’s clinical-stage pipeline, particularly Lacutamab and Monalizumab, holds potential in niche indications like CTCL and solid tumors, supported by partnerships with AstraZeneca and Sanofi. However, significant risks include its pre-revenue status (2023 revenue: $12.6M), negative net income (-$49.5M), and reliance on milestone payments from collaborators. The $66.4M cash position (2023) provides near-term runway, but further dilution or partnership deals may be necessary to fund Phase III trials. The stock’s beta of 0.94 suggests moderate volatility relative to the market. Investors should monitor clinical trial readouts and partnership milestones closely.
Innate Pharma competes in the crowded immuno-oncology sector by focusing on niche targets (e.g., KIR3DL2, CD73) and innate immunity mechanisms, differentiating itself from PD-1/PD-L1 dominant players. Its collaboration with AstraZeneca on Monalizumab (anti-NKG2A) provides validation but faces competition from Merck’s Keytruda and Bristol Myers’ Opdivo in the checkpoint inhibitor space. Lacutamab’s targeting of KIR3DL2 offers first-in-class potential in T-cell lymphomas, a market with limited therapies, though it competes with Acrotech Biopharma’s Folotyn and Adcetris. The company’s asset-light model via partnerships mitigates development costs but reduces control over commercialization. Its CD39/CD73 programs (IPH5201/IPH5301) compete with Arcus Biosciences’ etrumadenant and Corvus Pharmaceuticals’ ciforadenant in adenosine pathway inhibition. Innate’s strength lies in its specialized antibody engineering and early-mover advantage in NK cell engagement, but scalability remains a challenge against larger peers with deeper pipelines.